Microarray-based determination of ER, PR and HER2 receptor status: validation and comparison with IHC assessments

Publication Name: Poster, SABCS 2008

Author(s): Paul Roepman, Hugo Horlings, Oscar Krijgsman, Jolien Bueno-de-Mesquita, Richard Bender, Sabine Linn, Annuska Glas and Marc van de Vijver

In breast cancer patients the level of expression of estrogen receptor (ER), progesterone receptor (PR) and HER2 is predictive for prognosis and/or treatment response. However, differences in assessment methods and interpretation can substantially affect the accuracy and reproducibility of the … Continued

MammaPrint accurately identifies good prognosis group within clinically indeterminate risk patients.

Publication Name: Poster, ESMO 2008

Author(s): A. M. Glas , F. de Snoo, C. Dreezen, P. Roepman, R. Bender, L. Van ‘t Veer .

A 70-gene tumor expression profile was established as a powerful predictor of disease outcome in patients with breast cancer.(1,2) The test, known as “MammaPrint,” was validated in independent cohorts, and implementation was shown to be feasible in community hospitals.(3-7) We … Continued